GlassScriptPhysician profile
Brandi Samson
NPI 1457850497
$6,392.62
in general payments reported to CMS, 2019-2025
51 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,240 · 2022: $1,174 · 2023: $1,592 · 2024: $614 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,780 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,779.57 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $752.91 | 2021-2025 | Erleada, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $542.54 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $534.37 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $525.77 | 2021-2025 | Calquence, Enhertu, Lynparza |
| Glaxosmithkline, LLC. | $363.21 | 2021-2025 | Jemperli, Ojjaara, Shingrix |
| Abbvie INC. | $278.33 | 2021-2025 | |
| Genzyme Corporation | $226.93 | 2021-2025 | |
| Daiichi Sankyo INC. | $218.14 | 2021-2025 | Enhertu, Vanflyta, Datroway |
| Seagen INC. | $217.76 | 2022-2025 | Tukysa, Adcetris |
| Eisai INC. | $216.97 | 2022-2025 | |
| Celgene Corporation | $185.94 | 2021-2025 | Reblozyl, Opdivo, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $170.62 | 2021-2025 | Opdivo |
| Amgen INC. | $150.57 | 2021-2022 | |
| Tersera Therapeutics LLC | $134.73 | 2021-2025 | Zoladex, Xermelo |
| Takeda Pharmaceuticals U.S.A., INC. | $133.37 | 2023-2025 | Alunbrig, Iclusig |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $128.08 | 2025 | |
| Foundation Medicine, INC. | $123.59 | 2022 | |
| Aveo Pharmaceuticals, INC. | $111.89 | 2022-2025 | Fotivda |
| Epizyme, INC. | $95.29 | 2021 | |
| Genentech USA, INC. | $92.32 | 2021-2025 | Tecentriq, Itovebi |
| Taiho Oncology, INC. | $91.53 | 2021-2025 | |
| Lilly USA, LLC | $88.39 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $86.16 | 2021-2023 | Trodelvy |
| Incyte Corporation | $79.61 | 2021-2025 | Jakafi |
| Coherus Oncology, INC. | $72.79 | 2023-2025 | Loqtorzi |
| Ipsen Biopharmaceuticals, INC | $66.07 | 2021-2025 | Onivyde, Somatuline Depot |
| Kyowa Kirin, INC. | $53.29 | 2021-2023 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $46.35 | 2023 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $44.64 | 2022-2023 | Imbruvica |
| Janssen Scientific Affairs, LLC | $44.31 | 2023 | Tecvayli, Darzalex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.52 | 2021-2025 | |
| Beigene USA, INC. | $41.34 | 2021-2022 | |
| Stemline Therapeutics INC. | $40.24 | 2025 | Orserdu |
| Astellas Pharma US INC | $36.12 | 2025 | Vyloy |
| Beone Medicines USA, INC. | $33.56 | 2025 | Tevimbra |
| Tolmar, INC. | $33.24 | 2024-2025 | Rubraca |
| Array Biopharma INC | $30.65 | 2022-2023 | Mektovi, Xalkori, Braftovi |
| Dendreon Pharmaceuticals LLC | $26.79 | 2025 | Provenge |
| Legend Biotech USA INC. | $22.97 | 2025 | Carvykti |
| Pharmacosmos Therapeutics INC. | $22.81 | 2022 | |
| Exelixis INC. | $20.44 | 2025 | Cabometyx |
| Puma Biotechnology, INC. | $20.06 | 2023 | Nerlynx |
| Sandoz INC. | $19.09 | 2024 | Hyrimoz |
| Clovis Oncology, INC. | $18.18 | 2021 | |
| Pharmaessentia USA Corporation | $17.79 | 2023 | Besremi |
| G1 Therapeutics, INC. | $16.18 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.14 | 2025 | |
| Pharmaand Gmbh | $15.28 | 2025 | Rubraca |
| Sanofi-Aventis U.S. LLC | $14.62 | 2021 | |
| Blueprint Medicines Corporation | $14.18 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandi Samson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.